Fate Therapeutics
FATE
143 hedge funds and large institutions have $102M invested in Fate Therapeutics in 2025 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 44 increasing their positions, 38 reducing their positions, and 17 closing their positions.
129% more call options, than puts
Call options by funds: $112K | Put options by funds: $49K
35% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 17
16% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 38
14% more capital invested
Capital invested by funds: $88.9M → $102M (+$12.6M)
3% more funds holding
Funds holding: 139 → 143 (+4)
0.37% more ownership
Funds ownership: 69.51% → 69.87% (+0.37%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wilshire Advisors
Santa Monica,
California
|
+$9.15M |
| 2 |
Renaissance Technologies
New York
|
+$1.13M |
| 3 |
Two Sigma Investments
New York
|
+$725K |
| 4 |
Two Sigma Advisers
New York
|
+$555K |
| 5 |
GCM
Graham Capital Management
Rowayton,
Connecticut
|
+$413K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$4.01M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$2.78M |
| 3 |
Citigroup
New York
|
-$2.04M |
| 4 |
Morgan Stanley
New York
|
-$1.62M |
| 5 |
Goldman Sachs
New York
|
-$1.11M |
FATE Hedge Fund Activity: Q3 2025 in Review
143 of the 7,638 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q3 2025, worth a combined $102M — up 14% from $88.9M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new FATE positions and 17 closed out — a net gain of 6 holders — while 44 added to existing stakes and 38 trimmed.
The largest buyer was Wilshire Advisors, opening a new position worth an estimated $9.15M. The largest seller was Citadel Advisors, cutting an estimated $4.01M.
- 143 institutional investors held Fate Therapeutics (FATE) as of Q3 2025, up from 139 in Q2 2025.
- Funds reported $102M of Fate Therapeutics stock for Q3 2025, up 14% quarter-over-quarter.
- 23 funds opened new Fate Therapeutics positions in Q3 2025 and 17 closed out, a net change of +6 holders.
- The largest Fate Therapeutics buyer in Q3 2025 was Wilshire Advisors, an estimated $9.15M added.
- The largest Fate Therapeutics seller in Q3 2025 was Citadel Advisors, an estimated $4.01M sold.
Based on aggregated 13F filings for Q3 2025.